Sign in / Join Now
ETFs & Funds
Pink Sands Value Investor
I am in it to win it.......did we find support....by cheap sell high.....try it out.....but don't get greedy.
I am also in ARQL but now concerned about its movement, why its trending down? it should pop with Phase III trial positive data, thoughts?
Add a reply...
Latest StockTalks »
people get ARQL breaking news and analysis by email alert.
Get email alerts on ARQL »
Get latest price
From other sites
Data On Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition Of Wild Type And C481S Mutant BTK And Superiority To Ibrutinib In TCL1 Mouse Model Presented At The American Society Of Hematology Annual Meeting
at TheStreet (Sun, 9:00PM)
Preclinical Data On Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness In The Treatment Of Sickle Cell Disease Presented At The American Society Of Hematology Annual Meeting
at TheStreet (Sat, 5:45PM)
ArQule Reports Third Quarter 2016 Financial Results
at TheStreet (Nov 7, 2016)
Advancements In ArQule's Proprietary Pipeline To Be Highlighted At The 2016 American Society Of Hematology Annual Meeting
at TheStreet (Nov 3, 2016)
ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016
at TheStreet (Oct 24, 2016)